TABLE 4.
Surgical Results of Hyaloid Removal in Five Consecutive Cases with Vitreomacular Traction
| Patient Number |
Group | Lens Status | Follow-up (weeks) |
Preoperative Treatments |
Surgical Adjuvant |
Postoperative Treatments |
Baseline VA (ETDRS Chart) |
Final VA (ETDRS Chart) |
Change in VA (ETDRS Lines) |
Baseline OCT Foveal Thickness (micron) |
Final OCT Foveal Thickness (micron) |
Change in OCT Foveal Thickness (micron) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nonexudative AMD (Drusenoid PED) |
Phakic | 24 | None | None | None | 20/80 | 20/40 | +3 | 409 | 160 | −249 |
| 2 | Exudative AMD | Pseudophakic | 32 | PDT#2 Ranibizumab#3 Bevacizumab#3 |
C3F8 Bevacizumab | Bevacizumab#4 (2.5 mg) |
20/40 | 20/40 | 0 | 343 | 296 | −47 |
| 3 | Exudative AMD | Pseudophakic | 36 | Bevacizumab#6 | SF6 Bevacizumab | Bevacizumab#3 (2.5 mg) |
2/200 | 20/400 | +2 | 1103 | 224 | −879 |
| 4 | Exudative AMD | Pseudophakic | 24 | Bevacizumab#8 | Bevacizumab | Bevacizumab#6 (2.5 mg) |
20/400 | 20/320 | +1 | 1156 | 504 | −652 |
| 5 | Exudative AMD | Pseudophakic | 8 | FVT#2 PDT#1 Ranibizumab#9 |
SF6 Bevacizumab | Bevacizumab#2 (2.5 mg) |
20/400 | 20/320 | +1 | 858 | 858 | 0 |
| Mean ± SD | 20/250 | 20/150 | +1.4 ± 1.14 | 773.8 | 408.4 | −365.4 ± 385 | ||||||
| *P | .052 | .092s | ||||||||||
AMD = age-related macular degeneration; ETDRS = Early Treatment Diabetic Retinopathy Study; FVT = feeder vessel treatment; PED = pigment epithelial detachment; PDT = photodynamic therapy; SD = standard deviation.
*
Two-tailed paired Student t test.